• 66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts
  • Durable responses observed at Day 85: 83% (5/6) (10 mg) and 66.7% (4/6) (12 mg)